This article and associated images are based on a poster originally authored by Denise Sullivan, Zhong Yu, Benjamin Streeter, Stacie Chvatal and Daniel Millard and presented at ELRIG Drug Discovery ...
Toxicology profiling is a key part of drug discovery and safety as it provides a crucial means of ranking compounds for consideration in drug discovery. Traditionally toxicity testing has been carried ...
Medical device manufacturers use cytotoxicity testing to help prove that devices that come into contact with the human body are biocompatible. Testing results are critical for gaining market access, ...
Most cytotoxicity test “failures” trace back to controllable factors like device materials, sterilant or other chemical residues, or physicochemical characteristics of the extract - which means ...
Potency assay development uses DoE and QbD to improve accuracy, consistency, and regulatory readiness in biologics testing.
Superior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor modelsNovel RNA spliceosome-targeting payload PH1 ...
Understanding how drug discovery screening cascades are constructed and optimized is essential for minimizing false positives ...
An integrated suite of bioassays provides a coherent workflow to track antibody Fc effector activity across every stage of mAb drug development Potency assays that fail during tech transfer or ...
Automate real-time, label-free cell assays with Maestro TrayZ. Capture dynamic cellular responses with high sensitivity and ...
This article examines target-based vs phenotypic screening, comparing mechanisms, advantages, limitations, and use cases to guide screening strategy selection in drug discovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results